Thomas Gasser

88.8k total citations · 10 hit papers
544 papers, 35.4k citations indexed

About

Thomas Gasser is a scholar working on Neurology, Cellular and Molecular Neuroscience and Molecular Biology. According to data from OpenAlex, Thomas Gasser has authored 544 papers receiving a total of 35.4k indexed citations (citations by other indexed papers that have themselves been cited), including 329 papers in Neurology, 136 papers in Cellular and Molecular Neuroscience and 93 papers in Molecular Biology. Recurrent topics in Thomas Gasser's work include Parkinson's Disease Mechanisms and Treatments (246 papers), Neurological disorders and treatments (129 papers) and Neurological diseases and metabolism (67 papers). Thomas Gasser is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (246 papers), Neurological disorders and treatments (129 papers) and Neurological diseases and metabolism (67 papers). Thomas Gasser collaborates with scholars based in Germany, United States and Switzerland. Thomas Gasser's co-authors include Daniela Berg, Ronald B. Postuma, Glenda M. Halliday, Irene Litvan, Werner Poewe, José Á. Obeso, Günther Deuschl, Anthony E. Lang, Kenneth Marek and Christopher G. Goetz and has published in prestigious journals such as Science, The Lancet and Nucleic Acids Research.

In The Last Decade

Thomas Gasser

532 papers receiving 34.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

MDS clinical diagnostic criteria for Parkinson's disease

2015 4.8k citations Ronald B. Postuma, Daniela Berg et al. Movement Disorders profile →
MDS research criteria for prodromal Parkinson's disease

2015 876 citations Daniela Berg, Ronald B. Postuma et al. Movement Disorders profile →
Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria

2009 698 citations Dennis W. Dickson, Thomas Gasser et al. profile →
Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies

2011 660 citations Claudia Schulte, John Hardy et al. profile →
Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised, controlled trial

2011 599 citations Thomas Gasser et al. profile →
Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)

2012 560 citations Thomas Gasser et al. profile →
The phenotypic spectrum of CADASIL: Clinical findings in 102 cases

1998 502 citations Thomas Gasser et al. profile →
Update of the MDS research criteria for prodromal Parkinson's disease

2019 465 citations Daniela Berg, Thomas Gasser et al. Movement Disorders profile →
iPSC-derived neurons from GBA1-associated Parkinson’s disease patients show autophagic defects and impaired calcium homeostasis

2014 406 citations David C. Schöndorf, Benjamin Schmid et al. Nature Communications profile →
CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease

2024 34 citations Kathrin Brockmann, Stefanie Lerche et al. npj Parkinson s Disease profile →

Peers

Countries citing papers authored by Thomas Gasser

Since Specialization

Citations

This map shows the geographic impact of Thomas Gasser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Gasser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Gasser more than expected).

Fields of papers citing papers by Thomas Gasser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Gasser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Gasser. The network helps show where Thomas Gasser may publish in the future.

Co-authorship network of co-authors of Thomas Gasser

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Gasser. A scholar is included among the top collaborators of Thomas Gasser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Gasser. Thomas Gasser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Longitudinal cognitive decline characterizes the profile of non-PD-manifest GBA1 mutation carriers 2024 ·npj Parkinson s Disease ·Benjamin Röeben, Inga Liepelt‐Scarfone, Stefanie Lerche, Milan Zimmermann, Isabel Wurster, (unknown), Claudia Schulte, Christian Deuschle, Gerhard W. Eschweiler, Walter Maetzler, Thomas Gasser, Daniela Berg, Kathrin Brockmann	5
2	CSF α-synuclein seed amplification kinetic profiles are associated with cognitive decline in Parkinson’s disease breakdown → 2024 ·npj Parkinson s Disease ·Kathrin Brockmann, Stefanie Lerche, Simone Baiardi, Marcello Rossi, Isabel Wurster, Corinne Quadalti, Benjamin Röeben, Angela Mammana, Milan Zimmermann, Ann‐Kathrin Hauser, Christian Deuschle, Claudia Schulte, Inga Liepelt‐Scarfone, Thomas Gasser, Piero Parchi	34
3	Kinetic parameters of alpha-synuclein seed amplification assay correlate with cognitive impairment in patients with Lewy body disorders 2023 ·Acta Neuropathologica Communications ·(unknown), Marcello Rossi, (unknown), Thomas Henle, Thomas Gasser, Piero Parchi, Kathrin Brockmann, Björn Falkenburger	26
4	Evaluation of the Dementia Apraxia Test in Parkinson’s Disease Patients 2022 ·Dementia and Geriatric Cognitive Disorders ·(unknown), Sara Becker, Kathrin Brockmann, Thomas Gasser, (unknown), (unknown), Patricia Sulzer, Andreas Johnen, Inga Liepelt‐Scarfone	2
5	SWATH Mass Spectrometry-Based CSF Proteome Profile of GBA-Linked Parkinson’s Disease Patients 2022 ·International Journal of Molecular Sciences ·Saima Zafar, (unknown), Neelam Younas, Mohsin Shafiq, Matthias Schmitz, Isabel Wurster, Kathrin Brockmann, Thomas Gasser, Inga Zerr	4
6	Clonal hematopoiesis as a pitfall in germline variant interpretation in the context of Mendelian disorders 2022 ·Human Molecular Genetics ·Theresa Brunet, Riccardo Berutti, Veronika Dill, Judith S. Hecker, Daniela Choukair, (unknown), Marcus Deschauer, Janine Diehl‐Schmid, Martin Krenn, Gertrud Eckstein, Elisabeth Graf, Thomas Gasser, Tim M. Strom, Julia Hoefele, Katharina S. Götze, Thomas Meitinger, Matias Wagner	4
7	Cognitive-Driven Activities of Daily Living Impairment as a Predictor for Dementia in Parkinson Disease 2022 ·Neurology ·Sara Becker, (unknown), Kathrin Brockmann, Thomas Gasser, (unknown), (unknown), Hans‐Christoph Nuerk, Claudia Schulte, Walter Maetzler, Milan Zimmermann, Daniela Berg, Inga Liepelt‐Scarfone	13
8	CSF Protein Level of Neurotransmitter Secretion, Synaptic Plasticity, and Autophagy in PD and DLB 2021 ·Movement Disorders ·Stefanie Lerche, Simon Sjödin, Ann Brinkmalm, Kaj Blennow, Isabel Wurster, Benjamin Röeben, Milan Zimmermann, Ann‐Kathrin Hauser, Inga Liepelt‐Scarfone, Katharina Waniek, Ingolf Lachmann, Thomas Gasser, Henrik Zetterberg, Kathrin Brockmann	16
9	Quantifying activities of daily living impairment in Parkinson’s disease using the Functional Activities Questionnaire 2021 ·Neurological Sciences ·Sara Becker, Claire Pauly, Michael Lawton, Géraldine Hipp, Francesca Bowring, Patricia Sulzer, (unknown), Rejko Krüger, Thomas Gasser, Inga Liepelt‐Scarfone	3
10	Alpha-synuclein research: defining strategic moves in the battle against Parkinson’s disease 2021 ·npj Parkinson s Disease ·Luís M. A. Oliveira, Thomas Gasser, Robert H. Edwards, Markus Zweckstetter, Ronald Melki, Leonidas Stefanis, Hilal A. Lashuel, David Sulzer, Kostas Vekrellis, Glenda M. Halliday, Julianna J. Tomlinson, Michael G. Schlossmacher, Poul Henning Jensen, Julia M. Schulze‐Hentrich, Olaf Rieß, Warren D. Hirst, Omar M. A. El‐Agnaf, Brit Mollenhauer, Peter T. Lansbury, Tiago F. Outeiro	96
11	Interferon-γ signaling synergizes with LRRK2 in neurons and microglia derived from human induced pluripotent stem cells 2020 ·Nature Communications ·Vasiliki Panagiotakopoulou, Dina Ivanyuk, Silvia De Cicco, Wadood Haq, (unknown), Cong Yu, (unknown), (unknown), David C. Schöndorf, Maria Jose Perez J., (unknown), Meike Jakobi, Nicole Schneiderhan‐Marra, Thomas Gasser, Ivana Nikić, Michela Deleidi	87
12	CSF NFL in a Longitudinally Assessed PD Cohort: Age Effects and Cognitive Trajectories 2020 ·Movement Disorders ·Stefanie Lerche, Isabel Wurster, (unknown), Milan Zimmermann, Gerrit Machetanz, Sarah Wiethoff, (unknown), (unknown), (unknown), Christian Deuschle, Elke Stransky, (unknown), Thomas Gasser, Kathrin Brockmann	35
13	Parkinson’s disease: evolution of cognitive impairment and CSF Aβ_1–42 profiles in a prospective longitudinal study 2018 ·Journal of Neurology Neurosurgery & Psychiatry ·Stefanie Lerche, Isabel Wurster, (unknown), Gerrit Machetanz, Milan Zimmermann, Felix Bernhard, Elke Stransky, Christian Deuschle, Claudia Schulte, Oskar Hansson, Henrik Zetterberg, Thomas Gasser, Daniela Berg, Walter Maetzler, Kathrin Brockmann	17
14	The Birth of the Modern Era of Parkinson's Disease Genetics 2017 ·UCL Discovery (University College London) ·Andrew Singleton, John Hardy, Thomas Gasser	15
15	Generation of induced pluripotent stem cells derived from a 77-year-old healthy woman as control for age related diseases 2016 ·Stem Cell Research ·(unknown), (unknown), Mikkel A. Rasmussen, Christian Clausen, Ulrike A. Mau‐Holzmann, (unknown), (unknown), Thomas Gasser, Torsten Kluba, Bjørn Holst, Benjamin Schmid	2
16	Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease 2014 ·Movement Disorders ·Daniela Berg, Ronald B. Postuma, Bastiaan R. Bloem, Piu Chan, Bruno Dubois, Thomas Gasser, Christopher G. Goetz, Glenda M. Halliday, John Hardy, Anthony E. Lang, Irene Litvan, Kenneth Marek, José Á. Obeso, Wolfgang H. Oertel, C. Warren Olanow, Werner Poewe, Matthew Stern, Günther Deuschl	341
17	Acupuncture-Related Modulation of Pain-Associated Brain Networks During Electrical Pain Stimulation: A Functional Magnetic Resonance Imaging Study 2014 ·The Journal of Alternative and Complementary Medicine ·Nina Theysohn, Kyung‐Eun Choi, Elke R. Gizewski, Ming Wen, Thomas Rampp, Thomas Gasser, Gustav Dobos, Michael Forsting, Frauke Musial	19
18	A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder 2007 ·Brain ·Veerle Bogaerts, Sebastiaan Engelborghs, Samir Kumar‐Singh, D. Goossens, Barbara Pickut, Julie van der Zee, Kristel Sleegers, Karin Peeters, Jean‐Jacques Martin, Jurgen Del‐Favero, Thomas Gasser, Dennis W. Dickson, Zbigniew K. Wszołek, Peter Paul De Deyn, Jessie Theuns, Christine Van Broeckhoven	34
19	[A comparison of cholinesterase inhibitors and ginkgo extract in treatment of Alzheimer dementia]. 2001 ·PubMed ·(unknown), Thomas Gasser	5
20	Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma 2000 ·Cancer ·(unknown), Thomas Gasser, (unknown), J. Torhorst, Guido Sauter, Michael J. Mihatsch	373

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact